Oxervate
ApprovedSmall molecule
Oxervate is one of 52 small molecule programs targeting Eye Disease. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
200 competitors in Eye Disease
#DrugCompanyPhaseTrials
1Neoral
NovartisPhase 3
Alphagan
AbbViePhase 3
Chantix
PfizerPhase 3
Bayer Aspirin
BayerPhase 3
Zovirax
BBp Consulting, Inc
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
CF101
CCan-Fite BioPharma
Phase 3
Oxervate
DDompé Farmaceutici S.p.A
Approved
Carboxymethylcellulose
AbbViePhase 3
Csa
ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oxervate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- DDompé Farmaceutici S.p.A